MYSIMBA 8mg/90mg x 112 tabl
Mysimba is indicated as an adjunct to a reduced-calorie diet and increased physical activity.
weight control activity in adult patients (≥ 18 years) with a baseline BMI
body mass index (BMI)
≥30 kg/m2 (obesity), or
≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of one or more weight-related
comorbidities (e.g. type 2 diabetes, dyslipidemia or controlled
hypertension).
Mysimba treatment should be discontinued after 16 weeks if the patient has not lost
at least 5% of their initial body weight (see section 5.1).
Lemon balm extract + magnesium + vitamin B6